Amarin (AMRN) Surges Following Statistically Significant Study of AMR101
Tweet Send to a FriendGet Alerts AMRN Hot Sheet
Up)
Trade AMRN Now!
Shares of Amarin Corporation plc (Nasdaq: AMRN) are jumping 70 percent higher this morning after the company announced statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101.
The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.
Amarin said triglyceride levels decreased 21.5% and 10.1% from baseline versus placebo at 4 gram and 2 gram doses, respectively - LDL-C decreased at both doses within the predefined non-inferiority b.
Link to full release.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.
Amarin said triglyceride levels decreased 21.5% and 10.1% from baseline versus placebo at 4 gram and 2 gram doses, respectively - LDL-C decreased at both doses within the predefined non-inferiority b.
Link to full release.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin (AMRN) NCE Delay Not all Negative - MKM Partners
- No Split for Alcatel (ALU) as CEO Combes Looks to 'Slim-Down' Operations
- Amarin (AMRN) Vascepa NCE Not in Latest FDA Orange Book Update
Create E-mail Alert Related Categories
FDA, Hot FDA News, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
